Tarek Debs, Isabella Reccia^*, Imad El-Hajj, Ziad El-Rassi

Show more
Division of General and Visceral Surgery, Saint George Hospital University Medical Centre, Beirut, Lebanon.
Show less

Abstract: Cholangiocarcinoma is an uncommon malignancy that increases with age. Cholangiocarcinoma has been linked to inflammatory bowel disease, and a relationship between inflammatory bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually associated with ulcerative colitis, recently more cases are being seen in association with Crohn’s disease. The risk of cancer in patients treated with Infliximab has been discussed, and whether Infliximab is associated with an increased risk of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon malignancy and it is difficult to establish a clear correlation with Infliximab treatment. A large number of reports are needed to further address these issues. 

Keywords: Cholangiocarcinoma, Crohn’s, Inflammatory Bowel Disease, Infliximab

Cite this paper: Debs, T. , Reccia, I. , El-Hajj, I. and El-Rassi, Z. (2015) Cholangiocarcinoma in Patients with Crohn’s Disease. Journal of Cancer Therapy, 6, 21-24. doi: 10.4236/jct.2015.61003.

References

[1]   Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., Gaudio, E. and Alvaro, D. (2012) Cholangiocarcinoma: Epidemiology and Risk Factors. Translational Gastrointestinal Cancer, 1, 21-32.

[2]   Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., et al. (2011) Clinical Diagnosis and Staging of Cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology, 8, 512-522.
http://dx.doi.org/10.1038/nrgastro.2011.131

[3]   Patel, T. (2011) Cholangiocarcinoma—Controversies and Challenges. Nature Reviews Gastroenterology & Hepatology, 8, 189-200. http://dx.doi.org/10.1038/nrgastro.2011.20

[4]   Carriaga, M.T. and Henson, D.E. (1995) Liver, Gallbladder, Extrahepatic Bile Ducts, and Pancreas. Cancer, 75, 171-190.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2

[5]   Shaib, Y.H. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115-125. http://dx.doi.org/10.1055/s-2004-828889

[6]   Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
http://dx.doi.org/10.1136/gut.2008.155812

[7]   O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125

[8]   Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649. http://dx.doi.org/10.1097/MIB.0b013e318280ebbd

[9]   Lust, M. and Travis, S. (2009) Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy? Practical Gastroenterology. Inflammatory Bowel Disease.

[10]   Rojas-Feria, M., Castro, M., Suárez, E., Ampuero, J. and Romero-Gómez, M. (2013) Hepatobiliary Manifestations in Inflammatory Bowel Disease: The Gut, the Drugs and the Liver. World Journal of Gastroenterology, 19, 7327-7340. http://dx.doi.org/10.3748/wjg.v19.i42.7327

[11]   Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P. and Jess, T. (2010) Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 105, 1480-1487. http://dx.doi.org/10.1038/ajg.2009.760

[12]   Erichsen, R., Jepsen, P., Vilstrup, H., Ekbom, A. and S?rensen, H.T. (2009) Incidence and Prognosis of Cholangiocarcinoma in Danish Patients with and without Inflammatory Bowel Disease: A National Cohort Study, 1978-2003. European Journal of Epidemiology, 24, 513-520. http://dx.doi.org/10.1007/s10654-009-9365-4

[13]   Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. and Pallone, F. (2006) Infliximab and Newly Diagnosed Neoplasia in Crohn’s Disease: A Multicentre Matched Pair Study. Gut, 55, 228-233. http://dx.doi.org/10.1136/gut.2005.075937

[14]   Berman, M.D., Falchuk, K.R. and Trey, C. (1980) Carcinoma of the Biliary Tree Complicating Crohn’s Disease. Digestive Diseases and Sciences, 25, 795-797. http://dx.doi.org/10.1007/BF01345302

[15]   Krause, J.R., Ayuyang, H.Q. and Ellis, L.D. (1985) Occurrence of Three Cases of Carcinoma in Individuals with Crohn’s Disease Treated with Metronidazole. American Journal of Gastroenterology, 80, 978-982.

[16]   Altaee, M.Y., Johnson, P.J., Farrant, J.M. and Williams, R. (1991) Etiologic and Clinical Characteristics of Peripheral and Hilar Cholangiocarcinoma. Cancer, 68, 2051-2055. http://dx.doi.org/10.1002/1097-0142(19911101)68:9<2051::AID-CNCR2820680934>3.0.CO;2-M

[17]   Choi, P.M., Nugent, F.W., Zelig, M.P., Munson, J.L. and Schoetz Jr., D.J. (1994) Cholangiocarcinoma and Crohn’s Disease. Digestive Diseases and Sciences, 39, 667-670. http://dx.doi.org/10.1007/BF02088359

[18]   Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., Gaudio, E. and Alvaro, D. (2012) Cholangiocarcinoma: Epidemiology and Risk Factors. Translational Gastrointestinal Cancer, 1, 21-32.

[19]   Blechacz, B., Komuta, M., Roskams, T., Gores, G.J., et al. (2011) Clinical Diagnosis and Staging of Cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology, 8, 512-522.
http://dx.doi.org/10.1038/nrgastro.2011.131

[20]   Patel, T. (2011) Cholangiocarcinoma—Controversies and Challenges. Nature Reviews Gastroenterology & Hepatology, 8, 189-200. http://dx.doi.org/10.1038/nrgastro.2011.20

[21]   Carriaga, M.T. and Henson, D.E. (1995) Liver, Gallbladder, Extrahepatic Bile Ducts, and Pancreas. Cancer, 75, 171-190.
http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2

[22]   Shaib, Y.H. and El-Serag, H.B. (2004) The Epidemiology of Cholangiocarcinoma. Seminars in Liver Disease, 24, 115-125. http://dx.doi.org/10.1055/s-2004-828889

[23]   Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
http://dx.doi.org/10.1136/gut.2008.155812

[24]   O’Donnell, S., Murphy, S., Anwar, M.M., O’Sullivan, M., Breslin, N., O’Connor, H.J., Ryan, B.M. and O’Morain, C.A. (2011) Safety of Infliximab in 10 Years of Clinical Practice. European Journal of Gastroenterology & Hepatology, 23, 603-606. http://dx.doi.org/10.1097/MEG.0b013e3283479125

[25]   Hudesman, D., Lichtiger, S. and Sands, B. (2013) Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature. Inflammatory Bowel Diseases, 19, 644-649. http://dx.doi.org/10.1097/MIB.0b013e318280ebbd

[26]   Lust, M. and Travis, S. (2009) Is Anti-TNF Therapy Always Prohibited in Patients with Inflammatory Bowel Disease and Previous Malignancy? Practical Gastroenterology. Inflammatory Bowel Disease.

[27]   Rojas-Feria, M., Castro, M., Suárez, E., Ampuero, J. and Romero-Gómez, M. (2013) Hepatobiliary Manifestations in Inflammatory Bowel Disease: The Gut, the Drugs and the Liver. World Journal of Gastroenterology, 19, 7327-7340. http://dx.doi.org/10.3748/wjg.v19.i42.7327

[28]   Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P. and Jess, T. (2010) Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies. American Journal of Gastroenterology, 105, 1480-1487. http://dx.doi.org/10.1038/ajg.2009.760

[29]   Erichsen, R., Jepsen, P., Vilstrup, H., Ekbom, A. and S?rensen, H.T. (2009) Incidence and Prognosis of Cholangiocarcinoma in Danish Patients with and without Inflammatory Bowel Disease: A National Cohort Study, 1978-2003. European Journal of Epidemiology, 24, 513-520. http://dx.doi.org/10.1007/s10654-009-9365-4

[30]   Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., Meucci, G., Riegler, G., Petruzziello, C., Mocciaro, F., Geremia, A., Calabrese, E., Cottone, M. and Pallone, F. (2006) Infliximab and Newly Diagnosed Neoplasia in Crohn’s Disease: A Multicentre Matched Pair Study. Gut, 55, 228-233. http://dx.doi.org/10.1136/gut.2005.075937

[31]   Berman, M.D., Falchuk, K.R. and Trey, C. (1980) Carcinoma of the Biliary Tree Complicating Crohn’s Disease. Digestive Diseases and Sciences, 25, 795-797. http://dx.doi.org/10.1007/BF01345302

[32]   Krause, J.R., Ayuyang, H.Q. and Ellis, L.D. (1985) Occurrence of Three Cases of Carcinoma in Individuals with Crohn’s Disease Treated with Metronidazole. American Journal of Gastroenterology, 80, 978-982.

[33]   Altaee, M.Y., Johnson, P.J., Farrant, J.M. and Williams, R. (1991) Etiologic and Clinical Characteristics of Peripheral and Hilar Cholangiocarcinoma. Cancer, 68, 2051-2055. http://dx.doi.org/10.1002/1097-0142(19911101)68:9<2051::AID-CNCR2820680934>3.0.CO;2-M

[34]   Choi, P.M., Nugent, F.W., Zelig, M.P., Munson, J.L. and Schoetz Jr., D.J. (1994) Cholangiocarcinoma and Crohn’s Disease. Digestive Diseases and Sciences, 39, 667-670. http://dx.doi.org/10.1007/BF02088359